10-Q: Immunome Advances Oncology Pipeline, Boosts Cash

Immunome, Inc. reports increased R&D spending on key oncology programs and a strong cash position, despite continued operating losses and the termination of its AbbVie collaboration.

Summary

• Immunome, Inc. is a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted therapies for cancer patients.
• The company reported a net loss of $43.4 million for the three months ended June 30, 2025, compared to $36.1 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $85.0 million, a significant reduction from $165.6 million in the prior year, primarily due to lower in-process research and development (IPR&D) expenses.
• Collaboration revenue increased to $4.0 million for Q2 2025 (from $2.4 million in Q2 2024) and $6.9 million for H1 2025 (from $3.4 million in H1 2024), but the collaboration agreement with AbbVie terminated in July 2025.
• Research and development (R&D) expenses increased by $11.4 million to $40.5 million for Q2 2025 and by $32.9 million to $77.3 million for H1 2025, driven by increased activities for varegacestat and personnel costs.
• General and administrative (G&A) expenses rose to $10.0 million for Q2 2025 and $20.7 million for H1 2025, mainly due to increased personnel-related costs.
• As of June 30, 2025, the company held $143.9 million in cash and cash equivalents and $124.2 million in marketable securities, totaling $268.0 million in liquid assets.
• Net cash used in operating activities for the six months ended June 30, 2025, was $102.5 million, a substantial increase from $34.6 million in the prior year.
• The company completed a public offering in January 2025, raising net proceeds of $161.7 million.
• Immunome expects its existing cash, cash equivalents, and marketable securities to fund operations for at least 12 months from the filing date (August 6, 2025).
• The company will transition from an emerging growth company to a large accelerated filer effective December 31, 2025, and will no longer qualify as a smaller reporting company from Q1 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur significant operating losses and has a high cash burn rate, its strong cash position from recent financing provides a runway for at least 12 months. Pipeline assets are advancing into clinical stages, which is crucial for a biotech. The termination of the AbbVie collaboration is a negative, but the overall progress in the pipeline and financial stability for the near term balance this out. The upcoming transition to a large accelerated filer status indicates growth but also increased compliance costs.

Positives

• Net loss for the six months ended June 30, 2025, significantly decreased to $85.0 million from $165.6 million in the prior year, largely due to lower IPR&D expenses.
• The company maintains a strong liquidity position with $143.9 million in cash and cash equivalents and $124.2 million in marketable securities as of June 30, 2025.
• Varegacestat, a lead clinical asset for desmoid tumors, completed Phase 3 trial enrollment in February 2024, with topline data expected in the second half of 2025.
• Varegacestat received Orphan Drug Designation from the European Medicines Agency (EMA) in July 2025, following a similar designation from the U.S. FDA in November 2023.
• IM-1021, a ROR1 antibody-drug conjugate (ADC), initiated its Phase 1 clinical trial with the first patient dosed in February 2025, after receiving IND clearance in December 2024.
• IM-3050, a FAP-targeted radioligand therapy (RLT), received IND clearance in April 2025, with a Phase 1 trial expected to initiate in the second half of 2025.
• The company is advancing three preclinical solid tumor ADC drug candidates (IM-1617, IM-1340, IM-1335) through IND-enabling activities.
• Expanded its office and laboratory space in Bothell, Washington, by 13,000 square feet in June 2025, with tenant improvement allowances up to $9.3 million, supporting future growth.

Negatives

• Net loss increased for the three months ended June 30, 2025, to $43.4 million from $36.1 million in the prior year period.
• Net cash used in operating activities significantly increased to $102.5 million for the six months ended June 30, 2025, compared to $34.6 million in the prior year, indicating a higher cash burn rate.
• The collaboration agreement with AbbVie Global Enterprises Ltd., which was a source of collaboration revenue, terminated in July 2025, meaning no further revenue will be recognized from this agreement.
• The company has incurred significant operating losses since inception and expects to continue to incur losses for the foreseeable future, with no product revenue generated to date.
• Future funding requirements are substantial and depend on successful development and commercialization, which is uncertain and may require additional capital raises.
• Interest income decreased due to lower interest rates during the reporting period compared to the prior year.

Risks

• The company has a history of losses and expects to continue incurring significant losses, potentially never achieving or maintaining profitability.
• Limited operating history makes it difficult to evaluate drug development capabilities and predict future performance, as no drug has yet completed clinical development, obtained FDA approval, or been successfully commercialized.
• Varegacestat's prior development was not conducted by Immunome, and future clinical results may differ from prior data.
• There is a risk of being unable to advance product candidates through clinical development, obtain regulatory approvals, or commercialize them, or experiencing significant delays.
• The company may not be successful in its efforts to use and expand its ADC platform to build and progress a pipeline.
• Decisions on prioritizing specific programs or product candidates may prove incorrect and adversely impact the business.
• Failure to realize anticipated business benefits from completed or future strategic transactions, including potential unknown or contingent liabilities.
• The IM-3050 radioligand therapy program may face additional, unpredictable challenges related to obtaining raw materials, isotopes, suitable vendors, patient recruitment, and effective drug distribution due to the short half-life of Lu-177.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, with uncertain outcomes.
• Preliminary preclinical and clinical trial results may change as more data become available or undergo audit/verification.
• Difficulties in enrolling participants in clinical trials could delay or adversely affect clinical development activities.
• Delays in completing clinical trials may occur due to study design, particularly for event-driven studies like varegacestat's Phase 3 trial.
• Substantial competition exists from other companies developing cancer therapies, which may result in competitors commercializing products more quickly or successfully.
• Identification of undesirable side effects from product candidates could lead to regulatory delays, denials, or restrictive labeling.
• Reliance on third parties for preclinical studies, clinical trials, manufacturing, supply, and testing poses risks, including potential sole-source vendor issues and supply interruptions.
• Protecting intellectual property (IP) is difficult and costly, with risks of patent invalidation, unenforceability, or infringement by third parties.
• Inability to protect the confidentiality of trade secrets could harm the business and competitive position.
• Failure to attract and retain qualified key management, technical personnel, and employees would impair the ability to implement the business plan.
• The market price of common stock is expected to be volatile, and purchasers could incur substantial losses.
• Unfavorable global economic and political conditions, including tariffs, trade barriers, inflation, and geopolitical conflicts, could adversely affect business operations and financial results.
• Cyber attacks or breaches of information technology systems or data could lead to regulatory actions, litigation, fines, and business disruptions.
• Concentration of laboratory operations in one location makes the company vulnerable to natural or other disasters.
• Future changes in financial accounting standards or tax laws could adversely affect reported results or financial condition.
• Inability to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements.
• Significant costs are incurred as a result of operating as a public company, with management devoting substantial time to reporting and compliance initiatives.
• Inaccurate or unfavorable research by securities or industry analysts could cause stock price and trading volume to decline.
• Non-compliance with environmental, health, and human safety laws and regulations could adversely affect the business.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it develops therapeutic candidates. Existing cash, cash equivalents, and marketable securities are projected to fund operations for at least 12 months from the filing date. Additional financing may be required beyond this period through equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements to achieve longer-term business objectives. Research and development expenses are anticipated to increase substantially with the advancement and expansion of clinical development programs.

Management Comments

• We are a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.
• We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies.
• We believe that the pursuit of novel or underexplored targets will be central to the next generation of transformative therapies.
• Our goal is to establish a broad pipeline of preclinical and clinical assets and develop these assets into approved products for commercialization.
• We believe that IM-1021 may provide improved therapeutic index as compared to other ROR1-targeted ADCs in development.
• We believe this RLT approach (IM-3050) could overcome the limitations, such as poor internalization and low expression on tumor cells, that make FAP an unsuitable target for ADCs.
• We expect to continue to invest in discovery efforts intended to expand our pipeline, with additional ADC programs as the primary focus.
• We believe that our team's ADC expertise positions us to develop the next generation of transformative ADCs.

Industry Context

Immunome operates in the highly competitive and capital-intensive biotechnology industry, specifically within targeted oncology. The company's focus on antibody-drug conjugates (ADCs) and radioligand therapies (RLTs) aligns with growing trends in precision medicine for cancer treatment. The termination of the AbbVie collaboration highlights the inherent risks and evolving nature of partnerships in this sector. The competitive landscape includes large pharmaceutical companies and other early-stage biotechs, with increasing scrutiny on drug pricing and regulatory pathways. The company's transition to a large accelerated filer reflects its growth but also signals increased compliance burdens typical for more mature public biotechs.

Comparison to Industry Standards

• Varegacestat's Phase 2 RINGSIDE study Part A demonstrated objective response rates (ORR) of 75% in evaluable patients and 64% in the intent-to-treat population, with an 88% median reduction in tumor volume and 85% reduction in T2 imaging. This compares to SpringWorks Therapeutics, Inc.'s OGSIVEO (nirogacestat), an oral gamma secretase inhibitor, which received FDA approval in November 2023 for desmoid tumors, establishing a benchmark for efficacy and safety in this indication.
• IM-1021, a ROR1 ADC, is in Phase 1 clinical trial. This program faces competition from Merck's ROR1 ADC program (Zilovertamab vedotin) which is in a Phase 3 clinical trial for diffuse large B-cell lymphoma, and CStone Pharmaceuticals, Inc. which also has a ROR1 ADC program in clinical development. Immunome believes IM-1021 may offer an improved therapeutic index.
• IM-3050, a FAP-targeted lutetium-177 RLT, is expected to initiate a Phase 1 trial. This program competes with other FAP-targeted RLTs in clinical development from companies such as Novartis, Yantai LNC Biotechnology, and Perspective Therapeutics. The company's approach aims to overcome limitations of FAP as an ADC target.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential dilution from future equity offerings (including the remaining $180.0 million under the ATM agreement) and increased shares available under incentive plans. The stock price may be volatile due to inherent risks in drug development and market conditions. Increased compliance costs as a large accelerated filer may impact profitability.
• **Employees**: Continued investment in R&D and expansion of facilities may lead to increased hiring. Share-based compensation remains a significant component of personnel costs. The amendment to the 2024 Inducement Plan provides more opportunities for equity awards to new hires.
• **Customers (future)**: The advancement of clinical programs (Varegacestat, IM-1021, IM-3050) offers potential new treatment options for cancer patients, particularly those with desmoid tumors, solid tumors, and B-cell lymphomas.
• **Suppliers/Vendors**: Continued reliance on third-party contract manufacturers and other vendors for preclinical and clinical trial materials, manufacturing, and testing. Geopolitical conditions and trade restrictions could impact supply chains and costs.
• **Creditors**: The company's strong cash position and marketable securities provide financial stability in the near term, reducing immediate credit risk, but long-term funding needs remain.

Next Steps

• Report topline data from the Phase 3 registrational trial for varegacestat in the second half of 2025.
• Initiate a Phase 1 clinical trial for IM-3050 in the second half of 2025.
• Continue dose escalation for IM-1021 Phase 1 trial, including patients with solid tumors and B-cell lymphomas.
• Continue IND-enabling activities for preclinical assets IM-1617, IM-1340, and IM-1335.
• Evaluate and potentially pursue additional capital raises through equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements beyond the next 12 months.
• Comply with increased disclosure and compliance requirements as a large accelerated filer and non-smaller reporting company, effective December 31, 2025, and March 31, 2026, respectively.

Key Dates

Recommendation

Immunome is a clinical-stage oncology company with a promising pipeline, including a Phase 3 asset (Varegacestat) with topline data expected in H2 2025, and two other assets (IM-1021, IM-3050) entering Phase 1 trials. The company has a strong cash position of $268.0 million, providing a runway for at least 12 months. However, the cash burn from operating activities has significantly increased, and the collaboration revenue from AbbVie has terminated. The company will continue to incur substantial losses and will require significant additional capital for long-term development and commercialization. The inherent risks of drug development, intense competition, and upcoming increased compliance costs as a large accelerated filer suggest a 'hold' recommendation. Investors should monitor the upcoming Phase 3 data for Varegacestat and the progress of other clinical programs, as well as the company's ability to manage its cash burn and secure future financing.

Keywords

Oncology, Biotechnology, Clinical-stage, Antibody-drug conjugate, ADC, Radioligand therapy, RLT, Varegacestat, IM-1021, IM-3050, Desmoid tumors, ROR1, FAP, Cancer therapy, Drug development, SEC filing, 10-Q, Biopharmaceutical, Clinical trials, Preclinical, Targeted therapy